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Introduction. Coasting is the most commonly used strategy in prevention of severe OHSS. Serum FSH levels measurements during
coasting may aid in optimizing the duration of coasting. Objective(s). To study live birth rates (LBRs), clinical pregnancy rates
(CPRs), and optimal duration of coasting based on serum FSH levels on the hCG day. Materials and Methods. It is a retrospective
study performed between 2005 and 2008 at Barts and The London Centre for Reproductive Medicine, NHS Trust, London, UK,
on 349-coasted women undergoing controlled ovarian stimulation (COS) for IVF ± ICSI. The serum FSH level measurements on
the hCG day during coasting programme were analysed to predict the LBR and CPR. Result(s). LBR and CPR were signiﬁcantly
higher when the FSH levels on the hCG day were >2.5IU/L (LBR: 32.5%, P = 0.045 and CPR: 36.9%, P = 0.027) compared to FSH
<2.5IU/L. The optimal FSH cut-oﬀ level for LBR and CPR is 5.6IU/L on the hCG day. The optimal cutoﬀ for coasting is 4 days.
Conclusion(s). Coasting may be continued as long as either serum FSH level is > 2.5IU/L on the hCG day without compromising
the LBR and CPR or to maximum of 4 days.
1.Introduction
Ovarian hyperstimulation syndrome (OHSS) is a rare
iatrogenic complication of controlled ovarian stimulation
(COS). It is one of the unpleasant complications of the
gonadotrophin stimulation of the fertility treatment. The
pathophysiology of OHSS is not fully understood, but it
is hypothesized that clinical sequelae results in massive
ﬂuid shift in to the third space leading to intravascular
dehydration. This is due to increased vascular permeability
substances (VGEF and other growth factors). Although
OHSS is self-limiting, it is the most serious complication
of gonadotrophin stimulation with potentially serious and
rarely fatal outcomes. Currently optimal classiﬁcation of
OHSS is based on clinical, biochemical, and sonographic
parameters as follows described by Golan and Weissman.
Mild OHSS
Grade 1: Abdominal distention and discomfort.
Grade 2: Features of grade 1 plus nausea, vomiting,
and or diarrhea. Enlarged ovaries (5–12cm).
Moderate OHSS
Grade 3: Features of mild OHSS plus ultrasound
evidence of ascites.
Severe OHSS
Grade 4: Features of moderate OHSS plus clinical
evidence of ascites and or hydrothorax or breathing
diﬃculties.
Grade 5: All of the above plus change in blood
volume, increased viscosity due to haemoconcen-
tration, coagulation abnormalities, and diminished
renal perfusion and functions.
G r a d e6 :S e v e r eo rc r i t i c a l l yi l lp a t i e n t sa d m i t t e di n
intensive care involving multiple organ systems.
To date, there is no known pharmacological agent
that will cure OHSS. Hence, at best current treatment is2 International Journal of Endocrinology
empirical. Prevention or reducing the risk of OHSS still
remains the best option [1–13].
Withholding hCG administration, resulting in treatment
cancellation, remains the only method that will prevent
the development of severe OHSS [8, 13]. However, treat-
ment cancellation has signiﬁcant ﬁnancial and psychological
implications. Henceforth, many strategies for reducing the
risk of OHSS are tried. Coasting involves withdrawal of
exogenous gonadotrophin stimulation, in high risk patients,
once optimum follicular size has reached, and until the
serum oestradiol levels drop to, what is considered to be
a “safe” level to administer the hCG [4, 14, 15]. Coasting
resultsininhibitionandapoptosisofgranulosacellprolifera-
tionduetofallinglevelsofserumFSHandsubsequentlytheir
luteinisation [14]. This will prevent or reduce the cascade of
events that lead to severe OHSS [16].
Coasting is the most commonly used strategy in, pre-
vention of severe OHSS. Even though evidence is not strong
coasting played signiﬁcant role in the past to prevent OHSS
and it will be commonly employed in the future to prevent
OHSS in the absence of clear understanding of OHSS patho-
physiology. It also provides opportunity of pregnancy in the
i n d e xc y c l ea sw e l la sf r e e z i n go fs u r p l u se m b r y o sa n d
reduces the costs and the distress associated with the cycle
cancellation [4, 14, 17–20]. Recent Cochrane systematic
review reported beneﬁt of coasting in reducing OHSS but no
beneﬁt in pregnancy rates when compared with no coasting
[20].
Controversies still surrounds the coasting strategy re-
garding reduced number of oocytes retrieved, impaired im-
plantation, and pregnancy rates. In particular, the optimal
duration of coasting before hCG administration which will
not aﬀect pregnancy rates has not been elucidated [3, 15, 16,
21, 22].
The basis of serum FSH evaluation during coasting
evolved from the understanding of physiology of follicular
growth. Each follicle has a certain threshold level of FSH
below which follicular growth does not occur [23–25]. An
increase in the FSH level above the threshold level (after
exogenous gonadotrophin stimulation) can induce many
follicles to develop [24]. When serum FSH level falls below
the threshold level of the follicle, then that particular follicle
becomessusceptibletoapoptosis,resultinginatresia.Onthis
basis, the serum FSH levels should fall during coasting when
gonadotrophins are withheld, and this in turn can inﬂuence
ovarian response by decreasing the serum oestradiol levels
[24, 26, 27]. Thus, monitoring falling serum FSH levels
during coasting in addition to or alternative to serum
oestradiol levels can aid to decide the number of days of
coasting without compromising the outcomes.
Therefore, the aim of our study was to (1) investigate
whether serum FSH levels on the hCG day would predict the
clinical outcome in coasted women undergoing IVF ± ICSI
cycles at risk of developing severe OHSS and (2) to ﬁnd
out the serum FSH level during coasting at which hCG can
be administered safely without compromising the clinical
outcomes. This will subsequently help to determine the
optimal duration of coasting.
2.MaterialsandMethods
2.1. Study Design. This was a retrospective observational
study conducted at Barts and The London Centre for
Reproductive Medicine, NHS Trust, London, UK. Data from
349 women who were at risk of OHSS and were coasted
for more than one day while undergoing controlled ovarian
stimulation (COS) for IVF ±ICSI between 2005 and 2008.
2.2. Inclusion Criteria. Women who were at risk of OHSS
identiﬁed and coasted for more than one day while undergo-
ingcontrolledovarianstimulation(COS)forIVF±ICSI.The
riskofOHSSwomenidentiﬁedbasedonbiochemical(serum
E2 of >13000pmol/L), clinical (previous OHSS, high risk
patients as PCOS, <30 years, BMI <22, high response), and
sonographic (≥20 follicles and >20% of them are ≥15mm
diameter) parameters during gonadotrophin stimulation.
These women had their serum E2 and FSH levels measured
from the day of coasting until the day of hCG administration
onthehCGdayandsubsequentlyunderwentoocyteretrieval
fresh embryo transfer.
Ethical approval for this study was not required, since
it only involved the analysis of recorded data on the unit’s
database. The mandatory informed consent obtained from
all the women prior to the start of fertility treatment
according the HFEA (fertility governing body in UK) allows
the anonymous analysis of recorded data for clinical studies.
Allthe womenwereclearly informed that their recordeddata
offertility treatmentmaybe usedand analysedanonymously
for clinical studies prior to the start of the treatment.
2.3. Treatment Protocol. The COS for IVF ± ICSI was down-
regulation with agonist protocol and gonadotrophin stimu-
lationaspreviouslyreported[4].Inbrief,thepatientsunder-
went long downregulation with a gonadotrophin releasing
hormone (GnRH) agonist followed by gonadotrophin stim-
ulation with the dose selected on the basis of age, previous
response, early follicular phase serum FSH levels, and
body mass index (BMI). Gonadotrophins were administered
subcutaneously and the gonadotrophin used was urinary or
recombinant dependent upon the availability and cost. The
choice gonadotrophins did not inﬂuence outcomes in our
unitoveradecade.ThisisalsosupportedbyrecentCochrane
systematic review [28]. Follicular monitoring was performed
by transvaginal ultrasound, normally starting on day 9 of
gonadotrophin stimulation but in some selected cases, when
a high follicular response was anticipated (polycystic ovarian
syndrome, previous high response), it is started on day 7 of
stimulation.
MonitoringfortheriskofOHSSwasaccordingtocriteria
published earlier [26]. In brief, serum FSH and E2 were
measured when ultrasound scanning identiﬁed >20 follicles
(>5mm in mean diameter). When serum E2 was between
3000 and 13 200pmol/L, and the leading follicles were
>13mm in mean diameter the gonadotrophin dose was
halved. When serum E2 was >13 200pmol/L and the leading
follicles were >15mm in mean diameter gonadotrophins
were withheld hCG was administered when at least three
follicles reached a mean diameter of ≥18mm and serumInternational Journal of Endocrinology 3
Table 1: Demographic characteristics and variables of the study
population.
n = 349 Mean ±SD (range)
Age (years) 33.0 ±4.2 (21–44)
Body mass index (kg/m2)2 4 .7 ±4.5 (18–43)
Basal (day 1-2) FSH (IU/L) 6.6 ±2.0 (1.9–15)
Gonadotrophin start dose (IU) 211.5 ±78.0 (100–450)
Gonadotrophin total dose (IU) 1989 ±1139 (450–13500)
FSH on hCG administration day (IU/L) 9.8 ±5.7 (1–38)
Number of coasted days 2.08 ±1.2 (2–7)
Number of eggs collected 13.13 ±5.1 (2–38)
E2 level was <10000pmol/L. GnRH agonist was continued
until the day of the hCG administration. Routine IVF ± ICSI
laboratory procedures were used. The maximum numbers of
embryostransferredweretwoinmostofthecasesandinvery
few women who were above 40 years of age had maximum
of three embryos transferred. Vaginal progesterone pessaries
were prescribed for luteal support. A urinary pregnancy test
was performed 2 weeks following the embryo transfer and
pregnant women had a transvaginal ultrasound scan 4 weeks
later and all had conﬁrmation of pregnancy outcome.
2.4. Hormonal Assay. The serum FSH was analysed using
the Bayer immuno-1 automated analyser (Bayer, Newbury,
Bucks, UK) calibrated to WHO second international refer-
ence preparation with a <5% coeﬃcient of variation and
inter- and intracoeﬃcient of variation in the range of 1–
25IU/L and a sensitivity of 0.1IU/L.
The serum E2 measurements were also performed by
a Bayer immuno-1 automated analyser (Bayer, Newbury,
Bucks, UK) with a <5% coeﬃcient of variation in the range
75–13 200pmol/L.
2.5. Outcomes. Clinical pregnancy rate (CPR) was deﬁned
as sonographic conﬁrmation of an intrauterine gestation sac
with a positive foetal heart beat. Live birth rate (LBR) was
deﬁned as the delivery of at least one viable baby.
The main outcomes analysed were LBR and CPR in
relation to serum FSH level on the hCG day. The secondary
outcomes analysed were the correlation between serum FSH
level on the hCG day and age, BMI, basal FSH level,
starting dose of gonadotrophin, duration of gonadotrophin
administration, total dose of gonadotrophins administered,
the number of oocytes retrieved, and the duration of
coasting.
3.StatisticalAnalysis
The results were presented as means ± SD, percentages. The
data was analyzed for LBR and CPR at ﬁve homogenous
(Quintiles) serum FSH groups and also in (serum FSH
ranging from ≤5.2, >5.2 to ≤7.4, >7.4 to ≤9.8, >9.8 to
12.8, >12.8IU/L) on the day of hCG administration. This
is to identify serum FSH levels at which LBR and CPR
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Figure 1
were signiﬁcantly higher. Chi-square (χ2)t e s tw a sd o n e
as appropriate for comparison. P values of <0.05 were
considered statistically signiﬁcant.
The multivariate analyses were performed for the vari-
ables that could aﬀect serum FSH levels on the hCG day after
adjusting the confounders.
Receiver operating curve (ROC) analysis performed to
identify the optimal serum FSH level (cut-oﬀ level) for hCG
administration and also number days of coasting (duration
of coasting) in coasted patients. All data were analyzed Stats
Direct Statistical Software, version 2.7.7, London, UK.
4. Results
The demographic characteristics of the study population are
described in Table 1. The mean serum FSH level on the hCG
day was 9.8 ± 5.7IU/L (range 1–38).
Eight patients (2.3%) had serum FSH levels <2.5IU/L
and 73(20.3%) patients had <5.2IU/L on the day of hCG.
The LBR and CPR were signiﬁcantly higher when the FSH
level was >2.5IU/L than <2.5IU/L on the day of hCG (LBR:
32.5%, P = 0.027 and CPR: 36.9%, P = 0.045) (Table 2).
The CPR and LBR were also calculated in ﬁve homoge-
nous (Quintiles) groups of serum FSH levels (≤5.2, >5.2 to
≤7.4, >7.4 to ≤9.8, >9.8 to ≤12.8, >12.8IU/L) on the day of
hCG administration. Higher live birth rate was noticed only
in the serum FSH group ranging >5.2 to ≤7.4 in comparison
to ≤5.2 group but did not show any statistical diﬀerence
between other groups (Table 2 and Figure 1).
MultivariateanalysisshowedthatFSHlevelsonthedayof
hCG did not correlate with age, total dose of gonadotrophins
administered,orthenumberofoocytescollectedbutshowed
a negative correlation with BMI (P<0.0007), basal FSH
(P = 0.0377) and the number of coasting days (P<0.0001),4 International Journal of Endocrinology
Table 2: FSH levels (IU/L) and outcomes on the hCG administration day.
(a) CPR and LBR at FSH levels <2.5IU/L and >2.5IU/L
FSH levels at HCG trigger (IU/L) Number (%) n = 349 Clinical pregnancy rate CPR (%) Live birth rate LBR (%)
<2.5 8(2.3) 0 0
>2.5 341 (97.7) 126 (36.9) 111 (32.5)
Total 349 P = 0.027
∗ signiﬁcant P = 0.045
∗ signiﬁcant
(b) CPR and LBR at diﬀerent (Quintiles) FSH levels in IU/L
F S H N u m b e r( % ) C P R( % ) P value LBR (%) P value
FSH ≤5.2 73 (20.9) 21 (28.7) 0.09 16 (21.6) 0.02∗
signiﬁcant FSH >5.2–7.4 69 (19.7) 28 (40.5) 26 (37.6)
FSH >7.4–9.8 68 (19.4) 22 (32.3) 0.20 20 (29.4) 0.20
FSH >9.8–12.8 70 (20) 27 (38.5) 0.27 24 (34.2) 0.33
FSH >12.8 69 (19.7) 28 (40.5) 0.47 25 (36.2) 0.47
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Figure 2: Live births (LB): optimum cut-oﬀ FSH value: 5.6;
sensitivity: 78%; speciﬁcity: 27; ROC area under curve (AUC): 0.50
(95%CI:0.70to0.85).Clinicalpregnancies (CP):Optimumcut-oﬀ
FSH value: 5.6; sensitivity: 80%; speciﬁcity 30%; ROC area under
curve (AUC): 0.53 (95% CI: 0.73 to 0.85).
and a positive correlation with the starting dose of
gonadotrophins (P<0.003). This can be translated to a
single unit increase in BMI leads to a decrease in the serum
FSH level by 0.2IU/L on the day of hCG regardless of
start dose, duration of coasting, and pretreatment basal FSH
levels.Similarly,oneunitincreaseinthelevelofpretreatment
basal FSH leads to a decrease in the serum FSH level by
0.3IU/L on the day of hCG regardless of the start dose,
duration of coasting, and BMI.
The optimum cut-oﬀ v a l u e sf o rs e r u mF S Hl e v e l so nt h e
hCG day for both live births (LB) and clinical pregnancies
(CP) were 5.6IU/L with a sensitivity of 78% and 80% and
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Figure 3: Optimum cut-oﬀ point selected: 4; area under ROC
curve: 0.48; 95% CI: 0.45 to 0.56; sensitivity (95% CI): 0.18;
speciﬁcity (95% CI): 0.88.
with a speciﬁcity of 27% and 30% respectively. This indicates
that ROC curve did not predict absolute cut-oﬀ levels for
LBR and CPR in this study (Figure 2). ROC area under curve
(AUC) for live births (LB) and clinical pregnancies (CP) was
0.50 (95% CI: 0.70 to 0.85) and 0.53 (95% CI: 0.73 to 0.85),
respectively. The optimum cut-oﬀ value for number days of
coasting was 4 days with speciﬁcity of 88% and sensitivity of
12% indicating that chances of pregnancies after 4 days of
coasting are very slim (Figure 3).
When we analyzed the number of oocytes retrieved by
the number of days coasted, we noted that for each day
of coasting the number of oocytes retrieved decreased by a
factor of 0.6. The serum FSH declined 2.1IU/L per day of
coasting.International Journal of Endocrinology 5
5. Discussion
This study reports the ﬁrst large series to date on the corre-
lation between LBR, CPR, and serum FSH levels on the hCG
day. Results from our study suggests that serum FSH levels
>2.5IU/L on the day of hCG administration is asso-ciated
with a clinically improved CP and LB than when serum FSH
levels were <2.5IU/L on the day hCG in women coasted
to reduce risk of moderate/severe OHSS. Both CP and LB
were signiﬁcantly lower when FSH levels <2.5IU/L on the
day of hCG.
Arecentstudyof33-coastedcyclessuggestedanFSHcut-
oﬀ level of 4.9IU/L by ROC on the day of hCG for deciding
the duration of coasting [29].They have reported no concep-
tions in cycles below their identiﬁed optimum FSH cut-oﬀ
value (4.9IU/L). We have found pregnancies with serum
FSH level as low as 2.5IU/L on the hCG administration day
but not below the serum FSH level of <2.5IU/L. Compared
to them [27], ROC analysis in our study had the sensitivity at
80%, the speciﬁcity was low at 30%. The lack of good speci-
ﬁcity to identify the absolute cut-oﬀ value in this study may
be related to the diﬀerence in size of population compared.
Moreover, it is diﬃcult to compare and extrapolate our
results (live births and clinical pregnancies) with their results
(conceptions)[29]. It will be interesting to compare the
similar outcomes in a larger population. The CPR and LBR
were also calculated in ﬁve homogenous groups of serum
FSH range levels (≤5.2, >5.2 to ≤7.4, >7.4 to ≤9.8, >9.8
to ≤12.8, >12.8IU/L) on the day of hCG administration.
Higher live birth rate was noticed only in the serum FSH
groupranging>5.2 to ≤7 . 4i nc o m p a ri s o nt o≤5.2 group but
did not show a statistical diﬀerence between other groups.
Results from our earlier study has shown that serum
FSH declines steadily (approximately 25% per day) during
coasting, and the serum oestradiol will decline to a speciﬁc
level of <10,000pmol/L when FSH levels falls below the
threshold level of 5IU/L [25]. The optimum duration of
coasting to administer hCG without compromising the
pregnancy outcome may be decided on measurements of
serum FSH in conjunction with daily measurements of
serum oestradiol levels to ensure good clinical outcome
patient safety and reducing the risk of severe OHSS. It is
clinically useful to be aware that as serum FSH level declines
and approaches levels ≤5IU/L, careful decision making and
monitoring will be required to decide on when to administer
the hCG ﬁnal injection in costing program.
Many authors have reported lack of correlation of serum
E2 on hCG day and clinical outcome [13]. We did not
include data on serum E2 levels and its relation to changes
in serum FSH or correlation to clinical outcome in this
study, as we intended to study the beneﬁt of serum FSH
measurement during the coasting strategy. Further analysis
is in progress in our unit on this subject, where we intend
to study correlation of serum FSH levels and serum E2
levels in coasting strategies. The identiﬁed serum FSH cut-
oﬀ value of 5.6IU/L, below which pregnancies do not occur
in coasting programmes, needs to be further evaluated in
largeprospective,randomizedcontrolledtrialsinviewoflow
speciﬁcity.
In this study, the serum FSH level decrease by 2.1IU/L
and the number of oocytes retrieved decrease by a factor
of 0.6 with each day of coasting. Our results of oocyte
retrieval with respect to duration of coasting were com-
parable to earlier studies [16, 29, 30]. Other studies in
the literature reported signiﬁcant reduction in number
of oocytes retrieved after prolonged duration of coasting
with diﬀerent coasting strategies employed [13, 22]. The
most probable explanation for reduced oocyte retrieval after
prolonged coasting is due to poor follicular response (lack of
LH receptor upregulation) to the exogenous hCG (trigger)
subsequently leading to failure of ﬁnal oocyte maturation.
The oocytes that fail to undergo ﬁnal maturation cannot be
retrieved as they may stick to the follicular wall, hence, many
follicles that are matured by size may not yield any oocytes
[31].
The negative correlation of serum FSH level on the hCG
day to the BMI and pretreatment basal FSH is diﬃcult to
explain but may be associated with factors like absorption,
body fat distribution, and clearance [32]. The negative
correlation of serum FSH on the hCG day on the duration
of coasting is in agreement with other studies [22, 28, 33].
The duration of coasting will result in decreased serum FSH
level which is approximately a drop of 25%/day or 2.1IU/L
[27]. The drop in the serum FSH levels leads to the apoptosis
of granulosa cells during the coasting as explained in the
introduction [22, 26, 27]. We did not ﬁnd any studies in
the literature reporting the eﬀect of diﬀerent variables on the
serum FSH level on the hCG administration day.
More studies are required to evaluate the (a) eﬃcacy
of measuring serum FSH levels as a marker in coasting
programmes in addition to serum E2 on the hCG day even if
E2 is >10000pmol/L and (b) percentage drop of serum FSH
and oestradiol levels along with absolute cut-oﬀ values for
the serum FSH and E2 levels with respect to CPR and LBR
in coasted women to determine the optimum duration of
coastingpriortohCGadministrationwithoutcompromising
the outcomes.
We consider measuring serum FSH clinically beneﬁcial
to predict when serum E2 levels fall to safe levels and
may aid in identifying the best value of serum FSH and
E2 levels for best clinical outcome in coasting programme.
More studies are needed to evaluate the value of measuring
serum FSH in coasted women alongside in with serum E2
to determine the optimal duration of coasting or optimal
time to administer hCG without compromising the clinical
outcomes in coasting programmes. Further studies will assist
in determining the value of measuring serum FSH in COS in
general.
6. Conclusion
We conclude that in this study we noticed that LBR and
CPR were signiﬁcantly higher when serum FSH level was
>2.5IU/L on the hCG day. Our study also suggests LBR and
CPR may not compromise as along as serum FSH levels do
not fall below <2.5IU/L on the hCG day. Hence, we suggest
serum FSH monitoring during coasting programmes may
provide reassurance of eﬃcacy coasting programmes.6 International Journal of Endocrinology
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